CN1050905C - 前处理剂、前处理法、用处理试样的测定法和测定用药盒 - Google Patents
前处理剂、前处理法、用处理试样的测定法和测定用药盒 Download PDFInfo
- Publication number
- CN1050905C CN1050905C CN93107076A CN93107076A CN1050905C CN 1050905 C CN1050905 C CN 1050905C CN 93107076 A CN93107076 A CN 93107076A CN 93107076 A CN93107076 A CN 93107076A CN 1050905 C CN1050905 C CN 1050905C
- Authority
- CN
- China
- Prior art keywords
- beta glucan
- reagent
- reaction
- pretreating reagent
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 203
- 238000002203 pretreatment Methods 0.000 title claims abstract description 45
- 238000003556 assay Methods 0.000 title claims abstract description 9
- 208000035473 Communicable disease Diseases 0.000 title abstract description 5
- 238000003149 assay kit Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 120
- 239000002158 endotoxin Substances 0.000 claims abstract description 83
- 238000006243 chemical reaction Methods 0.000 claims description 127
- 239000006166 lysate Substances 0.000 claims description 59
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims description 45
- 229950007870 hexadimethrine bromide Drugs 0.000 claims description 45
- 241000239218 Limulus Species 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 39
- 241000239222 Tachypleus Species 0.000 claims description 32
- -1 hexadimethrine bromide compound Chemical class 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- 231100000284 endotoxic Toxicity 0.000 claims description 18
- 230000002346 endotoxic effect Effects 0.000 claims description 18
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 17
- 241001529572 Chaceon affinis Species 0.000 claims description 15
- 239000011159 matrix material Substances 0.000 claims description 15
- 150000004820 halides Chemical class 0.000 claims description 11
- 239000003513 alkali Substances 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 188
- 229920002498 Beta-glucan Polymers 0.000 abstract description 188
- 239000008280 blood Substances 0.000 abstract description 65
- 210000004369 blood Anatomy 0.000 abstract description 64
- 238000005842 biochemical reaction Methods 0.000 abstract description 18
- 239000000047 product Substances 0.000 abstract description 18
- 239000002244 precipitate Substances 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 230000002452 interceptive effect Effects 0.000 abstract 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 70
- 210000004623 platelet-rich plasma Anatomy 0.000 description 61
- 239000012085 test solution Substances 0.000 description 56
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 53
- 206010017533 Fungal infection Diseases 0.000 description 37
- 208000031888 Mycoses Diseases 0.000 description 37
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 31
- 238000002835 absorbance Methods 0.000 description 26
- 238000011084 recovery Methods 0.000 description 26
- 239000012530 fluid Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000007864 aqueous solution Substances 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 238000013016 damping Methods 0.000 description 21
- 230000008859 change Effects 0.000 description 20
- 239000012153 distilled water Substances 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- 239000000758 substrate Substances 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 238000012549 training Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000004108 freeze drying Methods 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 13
- 239000004094 surface-active agent Substances 0.000 description 13
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 12
- 241000222122 Candida albicans Species 0.000 description 12
- 229940095731 candida albicans Drugs 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 235000008599 Poria cocos Nutrition 0.000 description 9
- 241001619444 Wolfiporia cocos Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001112 coagulating effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 241001225321 Aspergillus fumigatus Species 0.000 description 8
- 229920000018 Callose Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229940091771 aspergillus fumigatus Drugs 0.000 description 8
- 238000010523 cascade reaction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000011888 autopsy Methods 0.000 description 7
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 7
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 6
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 6
- 241000222178 Candida tropicalis Species 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 201000007336 Cryptococcosis Diseases 0.000 description 5
- 241000221204 Cryptococcus neoformans Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 5
- 229960002509 miconazole Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000013223 septicemia Diseases 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical class [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- 238000004879 turbidimetry Methods 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 201000002909 Aspergillosis Diseases 0.000 description 4
- 208000036641 Aspergillus infections Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000014676 Phragmites communis Nutrition 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241000239224 Tachypleus tridentatus Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 4
- 229960003942 amphotericin b Drugs 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 229950005875 laurilsulfate Drugs 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- DELJNDWGTWHHFA-UHFFFAOYSA-N 1-azaniumylpropyl(hydroxy)phosphinate Chemical compound CCC(N)P(O)(O)=O DELJNDWGTWHHFA-UHFFFAOYSA-N 0.000 description 3
- GEHMBYLTCISYNY-UHFFFAOYSA-N Ammonium sulfamate Chemical compound [NH4+].NS([O-])(=O)=O GEHMBYLTCISYNY-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 238000006149 azo coupling reaction Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 108010071063 butyloxycarbonyl-leucyl-glycyl-arginine-4-nitroanilide Proteins 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 241000028466 Escherichia coli O111 Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 241001396014 Priacanthus arenatus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XEJCDBUNISUVGZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;dihydrochloride Chemical compound Cl.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 XEJCDBUNISUVGZ-XRIGFGBMSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- AJDONJVWDSZZQF-UHFFFAOYSA-N 1-(2,4,4-trimethylpentan-2-yl)-4-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]benzene Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OC1=CC=C(C(C)(C)CC(C)(C)C)C=C1 AJDONJVWDSZZQF-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000239219 Carcinoscorpius rotundicauda Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 1
- 241000239220 Limulus polyphemus Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- OCDXZFSOHJRGIL-UHFFFAOYSA-N cyclohexyloxycyclohexane Chemical compound C1CCCCC1OC1CCCCC1 OCDXZFSOHJRGIL-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- UQVDQSWZQXDUJB-UHFFFAOYSA-N hydron;7h-purin-6-amine;chloride Chemical compound Cl.NC1=NC=NC2=C1NC=N2 UQVDQSWZQXDUJB-UHFFFAOYSA-N 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 description 1
- FFJMLWSZNCJCSZ-UHFFFAOYSA-N n-methylmethanamine;hydrobromide Chemical compound Br.CNC FFJMLWSZNCJCSZ-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229940066429 octoxynol Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP142010/1992 | 1992-05-08 | ||
| JP14201092 | 1992-05-08 | ||
| JP142010/92 | 1992-05-08 | ||
| JP10042693A JP3524120B2 (ja) | 1992-05-08 | 1993-04-02 | 前処理剤、前処理方法、前処理された試料による測定法、測定用キット及び試料の判定方法 |
| JP100426/93 | 1993-04-02 | ||
| JP100426/1993 | 1993-04-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1087724A CN1087724A (zh) | 1994-06-08 |
| CN1050905C true CN1050905C (zh) | 2000-03-29 |
Family
ID=26441462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93107076A Expired - Lifetime CN1050905C (zh) | 1992-05-08 | 1993-05-08 | 前处理剂、前处理法、用处理试样的测定法和测定用药盒 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5389547A (enExample) |
| EP (1) | EP0569033B1 (enExample) |
| JP (1) | JP3524120B2 (enExample) |
| CN (1) | CN1050905C (enExample) |
| DE (1) | DE69325848T2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2737514B2 (ja) * | 1992-01-24 | 1998-04-08 | 和光純薬工業株式会社 | エンドトキシン測定用試料の前処理方法 |
| CN1063489C (zh) * | 1993-06-29 | 2001-03-21 | 生化学工业株式会社 | 新多肽及编码该多肽的dna |
| JP3429036B2 (ja) * | 1993-09-30 | 2003-07-22 | 生化学工業株式会社 | エンドトキシンの特異的測定剤 |
| US5747663A (en) * | 1994-02-07 | 1998-05-05 | Qiagen Gmbh | Process for the depletion or removal of endotoxins |
| US5648230A (en) * | 1994-06-30 | 1997-07-15 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Endotoxin stabilizing agent, endotoxin composition and method for assaying endotoxin |
| EP0805161B1 (en) * | 1994-09-01 | 2003-10-15 | Seikagaku Corporation | (1-3)-beta-d-glucan-binding protein, antibody that recognizes the protein, and use of the protein and antibody |
| US5637474A (en) * | 1994-10-31 | 1997-06-10 | Wako Pure Chemical Industries, Ltd. | Process for measuring amount of endotoxin or (1→3)-β-D-glucan by kinetic turbidimetric method |
| ATE190725T1 (de) * | 1995-09-14 | 2000-04-15 | Unipath Ltd | Test für lipopolysaccharide antigene |
| EP0763737B1 (en) * | 1995-09-14 | 2000-03-15 | Unipath Limited | Assays for lipopolysaccharide antigens |
| US6084092A (en) * | 1997-01-31 | 2000-07-04 | The Collaborative Group, Ltd. | β(1-3)-glucan diagnostic assays |
| US6110692A (en) | 1996-05-01 | 2000-08-29 | The Collaborative Group, Ltd. | Receptor for underivatized aqueous soluble β(1-3)-glucan |
| US6168924B1 (en) | 1996-10-21 | 2001-01-02 | Seikagaku Kogyo Kabushiki Kaisha | Limulus reaction-activating substance, method for inactivating the substance and measuring its amount, and method for measuring limulus reaction |
| US6413715B2 (en) | 1997-01-31 | 2002-07-02 | The Collaborative Group | β(1-3)-glucan diagnostic assays |
| US6270982B1 (en) | 1997-10-09 | 2001-08-07 | Charles River Laboratories | Methods and compositions for the detection of bacterial endotoxins |
| EP0995803A3 (en) * | 1998-10-20 | 2001-11-07 | Matsushita Electric Industrial Co., Ltd. | Sample treating kit and sample treating method using the same for analysis with a biosensor |
| JP2005500520A (ja) * | 2001-06-28 | 2005-01-06 | ケンブレックス バイオ サイエンス ウォカーズビル インコーポレーティッド | エンドトキシンを検出するための方法および試薬 |
| DE602004024769D1 (de) * | 2003-03-17 | 2010-02-04 | Charles River Lab Inc | Methoden und zusammensetzungen für den nachweis mikrobieller verunreinigungen |
| DE602004028048D1 (de) * | 2003-12-22 | 2010-08-19 | Seikagaku Kogyo Co Ltd | Verfahren zur messung von lipoarabinomannan und dessen anwendung |
| DE102004025780B4 (de) * | 2004-05-26 | 2008-04-03 | Stief, Thomas, Dr.med. | Verfahren zur Anti-Limulus-Faktoren-unabhängigen Bestimmung der Lipopolysaccharid- und/oder Lipid-A- und/oder Glukan-Reaktivität, dafür geeignetes Testsystem sowie dessen Verwendung |
| JP2008522640A (ja) * | 2004-12-02 | 2008-07-03 | チャールズ リバー ラボラトリーズ， インコーポレイテッド | グラム陽性菌夾雑物の検出および／または定量化のための方法ならびに組成物 |
| EP1836492B1 (en) | 2005-01-13 | 2008-12-31 | Charles River Laboratories, Inc. | Method for classifying a microorganism in a biological sample |
| WO2006080448A1 (ja) | 2005-01-27 | 2006-08-03 | Seikagaku Corporation | リムルス測定用前処理剤 |
| WO2006137444A1 (ja) * | 2005-06-22 | 2006-12-28 | Seikagaku Corporation | リポアラビノマンナンの反応性除去方法とその応用 |
| JP2007121205A (ja) * | 2005-10-31 | 2007-05-17 | Denka Seiken Co Ltd | ポリアミンを用いた免疫測定法用検体処理液組成物及びキット、並びにこれらを用いる免疫測定法 |
| JP4718301B2 (ja) * | 2005-10-31 | 2011-07-06 | デンカ生研株式会社 | 塩基性多糖類を含有する免疫測定法用検体処理液組成物及びキット、並びにこれらを用いる免疫測定法 |
| US20090286692A1 (en) * | 2008-04-15 | 2009-11-19 | Wainwright Norman R | Cartridge and Method for Sample Analysis |
| JP5437660B2 (ja) | 2009-02-19 | 2014-03-12 | 興和株式会社 | コアギュロゲン原料及びその製造方法、それを用いた生物由来の生理活性物質の測定方法及び測定装置 |
| WO2010107068A1 (ja) * | 2009-03-17 | 2010-09-23 | 和光純薬工業株式会社 | β－グルカンの測定方法及びそれに用いられるβ－グルカン結合性蛋白質 |
| AU2010265985B2 (en) | 2009-06-26 | 2016-04-21 | Charles River Laboratories, Inc. | Heat-treated Limulus amebocyte lysates |
| CN102841205A (zh) * | 2011-07-19 | 2012-12-26 | 辽宁思百得医药科技有限公司 | 一种检测注射用氟罗沙星细菌内毒素的方法 |
| CN109085357B (zh) * | 2012-12-28 | 2021-09-21 | 生化学工业株式会社 | 付之鲎试验的抗凝血酶iii用的前处理剂及前处理方法 |
| CN103214566A (zh) * | 2013-03-30 | 2013-07-24 | 福州新北生化工业有限公司 | 一种g因子的分离纯化方法 |
| CN105021817B (zh) * | 2014-04-24 | 2017-02-15 | 天津汇滨生物科技有限公司 | 一种人体液的显色法真菌1,3‑β‑D‑葡聚糖检测试剂盒 |
| CN104502612A (zh) * | 2015-01-09 | 2015-04-08 | 长春理工大学 | 一种特异性蛋白检测β-葡聚糖的比浊法 |
| JP6712160B2 (ja) * | 2016-03-29 | 2020-06-17 | 株式会社Adeka | エンドトキシン測定のための前処理方法及びその測定方法 |
| CN108362542A (zh) * | 2018-01-23 | 2018-08-03 | 福州启新生物技术有限公司 | 一种抗干扰碱试剂及其制备、使用方法 |
| CN112424602B (zh) * | 2018-07-27 | 2024-09-06 | 积水医疗株式会社 | 生物样品中(1→3)-β-D-葡聚糖的免疫分析方法、(1→3)-β-D-葡聚糖分析试剂盒以及(1→3)-β-D-葡聚糖免疫分析方法中使用的生物样品碱性预处理溶液 |
| CN109387637A (zh) * | 2018-10-12 | 2019-02-26 | 四川升和药业股份有限公司 | 丹参注射液细菌内毒素检测方法 |
| CN109580925A (zh) * | 2018-10-23 | 2019-04-05 | 东软威特曼生物科技(南京)有限公司 | 一种用于体外诊断试剂的复合反应促进剂 |
| WO2022081815A1 (en) * | 2020-10-14 | 2022-04-21 | Pickens Peter Vincent | Optimized detection of blood-borne microbes |
| CN113607903B (zh) * | 2021-07-30 | 2024-03-15 | 振德医疗用品股份有限公司 | 一种检测含有正电荷聚合物细菌内毒素的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1325043A (en) * | 1969-08-04 | 1973-08-01 | Greenspan D J | Method of separating blood components |
| JPS5642590A (en) * | 1979-09-14 | 1981-04-20 | Baxter Travenol Lab | Biological extracting liquid and production thereof |
| US4476093A (en) * | 1980-09-30 | 1984-10-09 | The Green Cross Corporation | Kit for preparing sample for use in endotoxin test |
| US4414336A (en) * | 1981-01-28 | 1983-11-08 | The Green Cross Corporation | Method for preparing sample for use in endotoxin test |
| EP0064293B1 (en) * | 1981-05-06 | 1986-12-10 | Asahi Kasei Kogyo Kabushiki Kaisha | Process for the production of hexafluoropropylene oxide |
| JPS5885162A (ja) * | 1981-11-16 | 1983-05-21 | Seikagaku Kogyo Co Ltd | エンドトキシン測定法 |
| DE3413311A1 (de) * | 1984-04-09 | 1985-10-17 | Behringwerke Ag, 3550 Marburg | Reagenz zur bestimmung der thromboplastinzeit |
| US4606824A (en) * | 1984-10-26 | 1986-08-19 | Chaokang Chu | Modified cellulose separation matrix |
| US5250436A (en) * | 1984-11-28 | 1993-10-05 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
| EP0186476A3 (en) * | 1984-12-21 | 1987-10-21 | Hemochek Corporation | Diagnostic kit and method for assaying blood components |
| JPS6426503A (en) * | 1987-07-22 | 1989-01-27 | Nisshin Kagaku Kogyo Kk | Antifouling agent for cultured shellfishes |
| JPS6426502A (en) * | 1987-07-22 | 1989-01-27 | Shikoku Chem | Sterilization and disinfection tablet containing chloroisocyanuric acid |
| CA1328074C (en) * | 1988-09-01 | 1994-03-29 | Shigenori Tanaka | Horseshoe crab amebocyte lysate factor g inhibitor |
| JP2957251B2 (ja) * | 1990-09-28 | 1999-10-04 | 生化学工業株式会社 | エンドトキシンの測定法 |
| US5185264A (en) * | 1990-11-09 | 1993-02-09 | Abbott Laboratories | Diluent buffer and method for diluting an assay component |
-
1993
- 1993-04-02 JP JP10042693A patent/JP3524120B2/ja not_active Expired - Lifetime
- 1993-05-07 DE DE69325848T patent/DE69325848T2/de not_active Expired - Lifetime
- 1993-05-07 EP EP93107479A patent/EP0569033B1/en not_active Expired - Lifetime
- 1993-05-08 CN CN93107076A patent/CN1050905C/zh not_active Expired - Lifetime
- 1993-05-10 US US08/058,306 patent/US5389547A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69325848D1 (de) | 1999-09-09 |
| EP0569033B1 (en) | 1999-08-04 |
| EP0569033A2 (en) | 1993-11-10 |
| CN1087724A (zh) | 1994-06-08 |
| EP0569033A3 (enExample) | 1994-04-06 |
| JP3524120B2 (ja) | 2004-05-10 |
| JPH0670796A (ja) | 1994-03-15 |
| DE69325848T2 (de) | 1999-12-23 |
| US5389547A (en) | 1995-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1050905C (zh) | 前处理剂、前处理法、用处理试样的测定法和测定用药盒 | |
| CN1105757A (zh) | 用于内毒素测定的试剂以及使用该试剂进行测定的方法 | |
| CN1215333C (zh) | 凝聚免疫分析法及其试剂 | |
| CN1505759A (zh) | 念珠菌的检测 | |
| CN101062939A (zh) | 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒 | |
| CN1030138A (zh) | 一种测定样品中内毒素存在的方法 | |
| CN101074962A (zh) | Abo血型反定型试剂 | |
| CN1796997A (zh) | 诊断ra的检测试剂盒、制备及完成质量检测标准的方法 | |
| CN1185161A (zh) | (1→3)－β－葡聚糖结合性蛋白质、识别该蛋白质的抗体及其利用 | |
| CN1920520A (zh) | 检测肝癌甲胎蛋白异质体的预装离心柱及含有该离心柱的试剂盒 | |
| CN101051010A (zh) | 一种检测糖链异常IgA肾病的装置及应用此装置的试剂盒 | |
| CN107870170A (zh) | 一种酶化学发光法测定糖化血清白蛋白的试剂盒 | |
| CN1153971C (zh) | 沙门氏菌抗原制剂和测定沙门氏菌抗体的试剂盒 | |
| CN1535380A (zh) | 鉴定微生物 | |
| CN1198815A (zh) | 用于测定细胞功能的容器、用于测定细胞功能的试剂盒以及用于测定细胞功能的方法 | |
| CN110283880A (zh) | 一种测定蛋白酶活力的新方法 | |
| CN1924583A (zh) | Abo血型反定型试剂 | |
| CN1427258A (zh) | 人尿中低密度脂蛋白含量酶联免疫吸附试验试剂盒及制备方法 | |
| CN1215332C (zh) | 采用不溶性载体粒子的免疫测定方法、免疫测定试剂及其稳定化方法 | |
| US20230258647A1 (en) | Hybrid amebocyte lysate and uses thereof | |
| US20240125789A1 (en) | Hybrid amebocyte lysate and uses thereof | |
| CN1588007A (zh) | 一种多糖定量检测方法及系统 | |
| CN1766632A (zh) | 一种检测动物源性食品中氟喹酮类药物的酶联免疫试剂盒 | |
| CN1773282A (zh) | 用于免役介导1型糖尿病诊断的自身抗体检测方法 | |
| CN111141856A (zh) | 同时检测发酵液中l-高丝氨酸和游离氨基酸的hplc方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20130508 Granted publication date: 20000329 |